Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy

Elena Schnabel‐Besson, Maximilian Knoll, Christian Schwager, Rolf Warta, Andreas Möck, Benito Campos, Laila König, Christine Jungk, Wolfgang Wick, Andreas Unterberg, Jürgen Debus, Christel Herold‐Mende, Amir AbdollahiInternational Journal of Molecular Sciences 2021 · DOI

TL;DR

This study identifies specific microRNAs (miRs) as potential prognostic biomarkers for glioblastoma (GBM) patients undergoing standard postoperative radiotherapy. The researchers found that lower levels of miR-221/222 are associated with improved survival, and this finding holds true across two independent patient cohorts, suggesting their utility in predicting patient outcomes.

What Problem Does This Paper Address?

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer, and despite multimodal treatment including surgery, radiotherapy, and chemotherapy, patient prognosis remains poor. While certain molecular markers like MGMT methylation and IDH1 mutations are known prognostic indicators, there's a significant need for additional biomarkers to better stratify patients and predict treatment response. MicroRNAs (miRs), small non-coding RNA molecules that regulate gene expression, are increasingly recognized for their roles in cancer development and progression. This paper aims to systematically investigate the prognostic value of specific miR families (miR-221/222 and miR-17-92) in GBM patients treated with standard postoperative radiotherapy, seeking to identify new biomarkers for improved patient management.

Methods

The study employed a two-cohort approach for hypothesis generation and validation.

  • Discovery Cohort (TCGA): The researchers utilized the Cancer Genome Atlas (TCGA) dataset, which contains microarray data for microRNA expression and survival information from 482 primary GBM patients. They performed univariate Cox proportional hazard (Cox-PH) analyses to identify miRs significantly associated with overall survival (OS).
  • Validation Cohort (HD): Candidate miRs identified in the TCGA cohort were then validated using quantitative reverse transcription PCR (qRT-PCR) on an independent cohort of 109 primary GBM patients treated at Heidelberg University Hospital (HD).
  • Statistical Analysis: Cox-PH models were used for both univariate and multivariate analyses to assess the prognostic value of miRs, considering demographic factors (age, sex, Karnofsky performance index), molecular markers (MGMT methylation, IDH mutation status), and treatment (postoperative radiotherapy) as covariates. Likelihood ratio tests were used for group comparisons.

Datasets

  • The Cancer Genome Atlas (TCGA) Glioblastoma Multiforme (GBM) Cohort: This dataset served as the discovery cohort, comprising 482 patients with microRNA expression data (Agilent 8x15K human microRNA microarrays) and associated survival data.
  • Heidelberg University Hospital (HD) Cohort: This cohort served as the validation dataset, consisting of 109 primary GBM patients treated at the hospital. MicroRNA expression was measured using qRT-PCR.

Key Insights and Ideas

  • miR-221/222 as Negative Prognostic Markers: The most striking finding is that high expression of miR-221 and miR-222 is associated with shorter overall survival in GBM patients. This suggests these miRs may act as "oncomiRs" (oncogenic microRNAs) promoting tumor progression.
  • Independent Prognostic Value: Crucially, the reduced expression of miR-221/222 was found to be an independent prognostic marker, meaning its predictive power holds even when accounting for other important clinical and molecular factors like age, sex, KPI, MGMT methylation, IDH mutation status, and radiotherapy.
  • Contradictory Findings for miR-17-92 Family: While miR-221/222 showed consistent prognostic value, the miR-17-92 family exhibited more ambiguous and even contradictory results between the TCGA and HD cohorts. This highlights the complexity of miR function and the need for further investigation.
  • Potential for Targeted Therapy: The identification of specific miRs with prognostic value opens avenues for developing targeted therapies aimed at modulating these miRs to improve patient outcomes.

Key Results

  • In the TCGA cohort, 50 miRs showed a significant association with survival.
  • miR-221/222: High expression of miR-221/222 was consistently associated with shorter survival in both the TCGA and HD cohorts.
  • In TCGA, median survival was 12.2 months for high miR-222 expressors vs. 16.9 months for low expressors.
  • In HD, median survival was 16 months for miR-221 and 17 months for miR-222 when comparing high vs. low expression groups.
  • Multivariate Analysis: miR-221/222 were confirmed as independent prognostic markers in multivariate analyses across both cohorts.
  • miR-17-92 Family: In the TCGA cohort, high expression of miR-17-92 family members was associated with prolonged survival. However, in the HD cohort, a significant prognostic separation was observed showing an unfavorable prognosis with high expression of miR-17-5p, miR-18a, and miR-19b.

Limitations and Future Work

  • miR-17-92 Family Ambiguity: The study acknowledges that the prognostic value of the miR-17-92 family members was ambiguous and contradictory between the two cohorts. This necessitates further validation in larger, prospective trials to clarify their role.
  • Mechanistic Studies Needed: While the study identifies prognostic miRs, it highlights the need for further mechanistic studies to fully understand the net effect of miR-221/222 expression on tumor microenvironment communication and response to therapy.
  • Potential for Targeted Intervention: The authors suggest that functional perturbation of miR-221/222 could be a promising avenue for targeted intervention in GBM patients.
  • High-LET Irradiation: The paper speculates on the interesting possibility of whether high-linear energy transfer (LET) irradiation could overcome the pro-invasive and radioresistant effects associated with miR-221/222 and miR-17-92.

Summary updated

Abstract

MicroRNAs (miRs) are non-coding master regulators of transcriptome that could act as tumor suppressors (TSs) or oncogenes (oncomiRs). We aimed to systematically investigate the relevance of miRs as prognostic biomarkers in primary glioblastoma multiforme (GBM) treated with postoperative radio(chemo)therapy (PORT). For hypothesis generation, tumor miR expression by Agilent 8x15K human microRNA microarrays and survival data from 482 GBM patients of The Cancer Genome Atlas (TCGA cohort) were analyzed using Cox-PH models. Expression of candidate miRs with prognostic relevance (miR-221/222; miR-17-5p, miR-18a, miR-19b) was validated by qRT-PCR using Taqman technology on an independent validation cohort of GBM patients (<i>n</i> = 109) treated at Heidelberg University Hospital (HD cohort). In TCGA, 50 miRs showed significant association with survival. Among the top ranked prognostic miRs were members of the two miR families miR-221/222 and miR-17-92. Loss of miR-221/222 was correlated with improved prognosis in both cohorts (TCGA, HD) and was an independent prognostic marker in a multivariate analysis considering demographic characteristics (age, sex, Karnofsky performance index (KPI)), molecular markers (O-6-methylguanine-DNA methyltransferase (MGMT) methylation, IDH mutation status) and PORT as co-variables. The prognostic value of miR-17-92 family members was ambiguous and in part contradictory by direct comparison of the two cohorts, thus warranting further validation in larger prospective trials.
BibTeX
@article{schnabelbesson2021prognostic,
  author = {Elena Schnabel‐Besson and Maximilian Knoll and Christian Schwager and Rolf Warta and Andreas Möck and Benito Campos and Laila König and Christine Jungk and Wolfgang Wick and Andreas Unterberg and Jürgen Debus and Christel Herold‐Mende and Amir Abdollahi},
  title = {{Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy}},
  journal = {International Journal of Molecular Sciences},
  year = {2021},
  doi = {10.3390/ijms22062960},
}
Figure